Moreover, DAA-treated cirrhotic subjects have even higher HCC risk if other risk factors are present, such as high liver stiffness, elevated AFP values, DM, or male sex, in analogy with what was described for IFN-based therapies [125,156]. The gene discussed is AFP; the disease is hepatocellular carcinoma.